Sun Pharma Receives ANVISA Approval to Manufacture Semaglutide in Brazil
Sun Pharmaceutical Industries Limited has secured approval from the Brazilian Health Regulatory Agency, ANVISA, for manufacturing and marketing its semaglutide injection within Brazil. The treatment is intended for adults with inadequately controlled type 2 diabetes mellitus when used as an adjunct to diet and exercise.The acquisition of this crucial market authorization signals a significant expansion opportunity for the company in Latin America. Sun Pharma plans to launch the product in the coming days through a partnership with Hypera Pharma, which is identified as a leading pharmaceutical company in Brazil.
The semaglutide injection will be available as a pre-filled, multi-dose injectable pen. It will come in two strengths: 2 mg/1.5 mL and 4 mg/3 mL, allowing for flexible, once-weekly dosing for patients.
Aalok Shanghvi, Chief Operating Officer at Sun Pharma, stated that the Brazilian approval expands access to an evidence-based treatment option for individuals managing inadequately controlled type 2 diabetes. He added that the achievement reflects the development and manufacturing capabilities of Sun Pharma and its commitment to providing high-quality medicines across global markets.
Digvijay Singh, Regional Head for Brazil and LATAM, commented on the approval, noting that it represents an important step in strengthening the company's diabetes portfolio in Brazil. He expressed enthusiasm regarding working with their partner to ensure this treatment option is available and to support improved diabetes care throughout the country.
Data points concerning the market are as follows:
| Market Segment | Estimated Value | Source/Date |
|---|---|---|
| Semaglutide Injectable Market in Brazil | USD 413 million | IQVIA, MAT June 2026 |
SUNPHARMA Stock Price Movement
Shares of Sun Pharmaceutical Industries Limited rallied on Wednesday, settling at ₹1989.90 after closing up 0.55% against the previous session’s close. The stock saw robust trading volume of 2.68 million shares and reached a strong intraday high of ₹1992.70.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.